Strategic Report on RNA Targeting Small Molecules Therapeutics Market: Growth Opportunities and Emerging Challenges
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global RNA Targeting Small Molecules Therapeutics Market Valued at Present and by 2029?
The market size for RNA targeting small molecules therapies has seen substantial growth in the last few years. The market is projected to increase from $6.1 billion in 2024 to $7.83 billion in 2025, with a compound annual growth rate (CAGR) of 28.3%. The historical growth is linked to factors such as drug discovery and development, the increasing incidence of RNA-related illnesses, funding from government and private entities, interest from the pharmaceutical industry, and successful cases with RNA therapeutics.
In the coming years, the market size for RNA targeting small molecules therapeutics is anticipated to experience an explosive growth. It is predicted to elevate to “$21.95 billion by 2029 with a compound annual growth rate (CAGR) of 29.4%. This anticipated growth in the projected period can be ascribed to factors such as precision medicine and personalized therapies, an increase in the identification of RNA biomarkers, an expansion of the RNA target spectrum, rising funding and investments, and its application in rare diseases. Some significant trends for the forecasted period encompass progress in screening technologies, dominance of antisense oligonucleotides, RNA binders of small molecules, RNA therapeutics application in neurological disorders, and gene editing utilizing the CRISPR-Cas9 technique.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp
#What Drivers Are Influencing Growth In The RNA Targeting Small Molecules Therapeutics Market?
The rise in cancer instances is predicted to accelerate the growth of the RNA-targeting small molecule therapeutics market. Cancer encompasses a variety of diseases that can arise in almost any organ or tissue when abnormal cells multiply uncontrollably, surpassing their usual constraints and either infiltrating other organs or intruding into adjacent body components. RNA-targeting small molecules, which are designed and studied to selectively target RNA sequences associated with cancer, are used in cancer treatment. For example, research issued by the American Cancer Society, a health organization based in the US, stated in January 2022 that approximately 609,360 cancer-related deaths and 1.9 million new cancer cases are predicted in the US in 2022, averaging about 1,670 deaths daily. As a result, the RNA-targeting small molecule therapeutics market’s growth is being fueled by the escalating number of cancer cases.
The rna targeting small molecules therapeutics market covered in this report is segmented –
1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings
2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications
3) By Application: Drug Discovery, Oncology Research, Disease Identification
4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation
2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides
3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers
4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability
What Notable Trends Are Shaping The Direction Of The RNA Targeting Small Molecules Therapeutics Market?
The increasing tendency towards strategic alliances is a prime trend observed in the RNA-targeting small molecule therapeutics market. Mainstream firms involved in this market are establishing partnerships to foster novel relationship dynamics that facilitate inventive product development. One example is the collaboration in June 2022 between Otsuka Pharmaceutical Co. Ltd., a Japanese pharmaceutical manufacturer, and xFOREST Therapeutics Co. Ltd., a fellow Japan-based drug discovery platform creator. Under this partnership, Otsuka will utilize the Forest technology provided by xFOREST to enhance its research in systemic small-molecule medication discovery, particularly in RNA structures. Moreover, in April 2024, Ipsen, a French biopharmaceutical enterprise, formed a partnership with Skyhawk Therapeutics, a clinical-stage biotechnology company based in the US which is known for its RNA-targeting small molecule therapeutics. The objective of this collaboration was to develop RNA-targeting small molecule medicines for infrequent neurological disorders and amalgamate diverse data sets to create and establish small molecules that have the ability to modulate RNA.
Which Companies Play A Key Role In The Development Of The RNA Targeting Small Molecules Therapeutics Market?
Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics
What Are The Key Regional Developments Shaping The RNA Targeting Small Molecules Therapeutics Market?
North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
